Ekso Bionics Announces Appointment of Christian Babini as Vice President of Sales, Americas
August 30 2017 - 9:00AM
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (“Ekso”), an industry
leader in exoskeleton technology for medical and industrial use,
today announced that Christian Babini has been appointed to the
role of Vice President of Sales, Americas.
“We are thrilled to welcome Christian to the
Ekso team,” commented Thomas Looby, Ekso’s President and Chief
Executive Officer. “He has built an impressive track record of
delivering outstanding results throughout his career, and we are
confident that his diverse and extensive experience will be an
invaluable asset as we ramp up our sales infrastructure and work
toward achieving our vision of improving the lives of patients
while creating value for our shareholders.”
Mr. Babini added, “I am excited to join Ekso
Bionics, a leader in the field of robotic technology, and lead the
Americas sales team. Ekso’s innovative exoskeleton portfolio
provides significant value to our customers, and I look forward to
helping accelerate our sales effort and expand our market
presence.”
Mr. Babini brings more than 20 years of diverse
medical device sales experience to Ekso. Most recently, he served
as Global Vice President, Sales and Market Development at Medtech
Surgical from 2014 until its acquisition by Zimmer Biomet in 2016.
Prior to that, he served as Regional Vice President of Sales at
Intuitive Surgical, Inc., where he contributed to a substantial
acceleration of robotic adoption and helped develop the sales
training program during his 10 years with the company. He
previously served in various sales leadership roles at U.S.
Surgical Corp. Mr. Babini earned a Bachelor of Science in
Communications from Eastern Michigan University.
About Ekso BionicsEkso Bionics
is a leading developer of exoskeleton solutions that amplify human
potential by supporting or enhancing strength, endurance and
mobility across medical, industrial and defense applications.
Founded in 2005, the company continues to build upon its
unparalleled expertise to design some of the most cutting-edge,
innovative wearable robots available on the market. Ekso Bionics is
the only exoskeleton company to offer technologies that range from
helping those with paralysis to stand up and walk, to enhancing
human capabilities on job sites across the globe, to providing
research for the advancement of R&D projects intended to
benefit U.S. defense capabilities. The company is headquartered in
the Bay Area and is listed on the Nasdaq Capital Market under the
symbol EKSO. For more information, visit: www.eksobionics.com.
Forward-Looking StatementsAny
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements.
Forward-looking statements may include, without limitation,
statements regarding (i) the plans and objectives of management for
future operations, including plans or objectives relating to the
design, development and commercialization of human exoskeletons,
(ii) estimates or projection of financial results, financial
condition, capital expenditures, capital structure or other
financial items, (iii) the Company's future financial performance
and (iv) the assumptions underlying or relating to any statement
described in points (i), (ii) or (iii) above. Such forward-looking
statements are not meant to predict or guarantee actual results,
performance, events or circumstances and may not be realized
because they are based upon the Company's current projections,
plans, objectives, beliefs, expectations, estimates and assumptions
and are subject to a number of risks and uncertainties and other
influences, many of which the Company has no control over. Actual
results and the timing of certain events and circumstances may
differ materially from those described by the forward-looking
statements as a result of these risks and uncertainties. Factors
that may influence or contribute to the inaccuracy of the
forward-looking statements or cause actual results to differ
materially from expected or desired results may include, without
limitation, the Company's inability to obtain adequate financing to
fund the Company's operations and necessary to develop or enhance
our technology, the significant length of time and resources
associated with the development of the Company's products, the
Company's failure to achieve broad market acceptance of the
Company's products, the failure of our sales and marketing
organization or partners to market our products effectively,
adverse results in future clinical studies of the Company's medical
device products, the failure to obtain or maintain patent
protection for the Company's technology, failure to obtain or
maintain regulatory approval to market the Company's medical
devices, lack of product diversification, existing or increased
competition, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC. To learn more about Ekso Bionics please visit us at
www.eksobionics.com. The Company does not undertake to update these
forward-looking statements.
Media Contact:
Carrie Yamond
917-371-2320
cyamond@lazarpartners.com
Investor Contact:
Matthew Ventimiglia
212-599-1265
investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024